EN | TR
E-ISSN: 3061-9947
Which Antibiotic Prophylaxis is Better to Prevent Infections after Transrectal Prostate Biopsy: Single or Combination?
PDF
Cite
Share
Request
Original Article
VOLUME: 54 ISSUE: 1
P: 57-62
2021

Which Antibiotic Prophylaxis is Better to Prevent Infections after Transrectal Prostate Biopsy: Single or Combination?

Acta Haematol Oncol Turc 2021;54(1):57-62
DOI: 10.5505/aot.2021.59489
Cem Şah 1
Deniz Abat 2
Adem Altunkol 3
Mehmet Salih Boğa 4
1. Urology Clinic, Medline Private Hospital, Adana, Turkey
2. Urology Cli̇ni̇c, Ministry of Health İskenderun State Hospi̇tal, Hatay, Turkey
3. Urology Clinic, University of Health Sciences Adana City Training and Research Hospital, Adana, Turkey
4. Urology Clinic, University of Health Sciences Antalya Training and Research Hospital, Antalya, Turkey
5.
No information available.
No information available
Received Date: 2020-10-05T22:07:18
Accepted Date: 2021-04-07T09:23:51
PDF
Cite
Share
Request

Abstract

INTRODUCTION

The aim of this study was to compare the effectiveness of three different prophylaxis methods after transrectal ultrasound-guided prostate biopsy.

METHODS

Patients who underwent a transrectal prostate biopsy were added to the study. Three different prophylactic antibiotic procedures were applied. In the first group, 62 patients received 500 mg ciprofloxacin orally, 87 patients in the second group received 500 mg ciprofloxacin orally plus one dose of 500 mg amikacin intramuscularly, and 91 patients in the third group received 500 mg ciprofloxacin orally plus one dose of 500 mg amikacin plus 500 mg metronidazole intravenously. Additionally, rectal cleansing with povidone-iodine was performed immediately before biopsy for patients in the third group. Demographic data, antibiotic use within the previous 6 months, comorbidite diseases, and presence of a urinary catheter were compared between the groups according to post-biopsy infection rates.

RESULTS

There were 62 patients in the first group, 87 patients in the second group and 91 patients in the third group. Post-biopsy infection was detected in 5 (8.1%) patients in the first group, 2 (2.3%) patients in the second group and 1 (1.1%) patient in the third group. There were statistically significant differences between the groups according to infection rates (p= 0.049). There were no significant differences between the groups according to the presence of diabetes, urethral catheterization and antibiotic use within the previous 6 months, which are risk factors for infection.

DISCUSSION AND CONCLUSION

Combination therapy is a more effective approach to prevent biopsy-related infectious complications than single agent therapy.